Lung cancer test kit TETRADECAN™

for genetic mutationsfor precision medicinegene MET

Lung cancer has the most established targeted therapy treatment landscape. Targeting specific genetic mutations, such as EGFR and BRAF mutations, ALK, ROS1 and NTRK gene rearrangements with drugs provides specificity towards cancer cells while sparing toxicity to normal cells and ultimately improving patient outcomes. Therefore, genetic testing is a crucial step in matching a patient to the right targeted therapy. Our lung cancer-specific panels can meet all of your clinical needs for lung cancer patients at all disease stages. Optional PD-L1 immunohistochemistry (IHC) test is available to better guide immunotherapy decisions. Targets 14 key genes in lung cancer Coverage of all exons and fusion-related introns in these genes to guide targeted therapy 8 genes recommended by the National Comprehensive Cancer Network (NCCN) Guideline for lung cancer treatment: EGFR, ALK, MET, KRAS, ERBB2 (HER2), ROS1, RET, BRAF 6 core genes in key signaling pathways associated with the efficacy of targeted therapy: NRAS, NF1, MAP2K1(MEK1), AKT1, PIK3CA, PTEN WHO IS IT FOR Newly diagnosed systemic treatment-naive lung cancer patients seeking targeted therapy SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others)